Silverarc Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Silverarc Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-290,600	Closed	-$4.69M	–	79
2025 Q4	$4.69M	Buy	+290,600	New	+$3.85M	0.65%	41
2024 Q1	–	Sell	-180,400	Closed	-$2.21M	–	87
2023 Q4	$2.21M	Sell	180,400 -350,000	-66%	-$3.18M	0.66%	45
2023 Q3	$5.11M	Buy	+530,400	New	+$5.42M	1.55%	27

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's KALV Position: Q2 2026 in Review

Silverarc Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,876,407 shares — an estimated $57.9M sold.

Silverarc Capital Management first reported a position in KALV in Q1 2021 and held it in 15 quarters. The position peaked at $57.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Silverarc Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 2,876,407 KalVista Pharmaceuticals shares in Q2 2026, an estimated $57.9M.
Silverarc Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 15 quarters.
Silverarc Capital Management's KalVista Pharmaceuticals position peaked at $57.9M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.